July 22, 2014
Full Schedule Now Available for CME-Certified
Cancer Immunotherapy Program in La Jolla, CA

Are you or someone you know looking for more information on the ground-breaking cancer treatment options that use the power of the immune system?
Who Should Attend
Specifically designed for clinical oncologists and the entire unit of care involved in treating cancer patients with immunotherapy, these introductory, CME-certified programs will provide an understanding of basic immunology principles in the clinical application and management of cancer immunotherapy and discuss emerging drugs and concepts in the cancer immunotherapy field.
Presented by leading authorities in tumor immunology and cancer immunotherapy, these programs will facilitate an understanding of:
- Underlying principles of tumor immunology and immunotherapy
- Clinical indications for cancer immunotherapy and appropriate selection of patients
- Patient management
- Therapeutic effectiveness of immunotherapy to ultimately improve patient outcomes
Program Schedule
8:00 am - 8:10 am
|
Welcome and Overview
|
Session I: Basic Principles of Tumor Immunology and Immunotherapy
2.25 AMA PRA Category 1 Credits™
|
8:10 am - 8:50 am
|
Immunology 101
Stephen P. Shoenberger, PhD – La Jolla Institute for Asthma and Immunology
|
8:50 am - 9:20 am
|
Inflammation and Tumor Development
Gregory A. Daniels, MD, PhD – University of California San Diego Cancer Center
|
9:20 am - 9:50 am
|
Immune Changes Associated with Tumor Growth and Regression
Jack D. Bui, MD, PhD – University of California, San Diego
|
9:50 am - 10:20 am
|
Panel Discussion
|
10:20 am - 10:35 am
|
Break
|
Session II: Targeting the Tumor
2 AMA PRA Category 1 Credits™
|
10:35 am - 11:05 am
|
Current State of Immune Checkpoint Inhibitors
Omid Hamid, MD – The Angeles Clinic and Research Institute
|
11:05 am - 11:35 am
|
Oncolytic Virus Therapy in Cancer Immunotherapy
Robert Hans Ingemar Andtbacka, MD, CM, FACS, FRCSC – University of Utah
|
11:35 am - 12:05 pm
|
Cell Therapy
Mark Faries, MD – The John Wayne Cancer Institute
|
12:05 pm - 12:35 pm
|
Panel Discussion and Case Studies
|
12:35 pm - 1:20 pm
|
Lunch
|
Session III: New Combination Strategies: When More is Better and Less May be More
2.25 AMA PRA Category 1 Credits™
|
1:20 pm - 1:50 pm
|
Combination Therapy
Bartosz Chmielowski, MD, PhD – University of California, Los Angeles
|
1:50 pm - 2:20 pm
|
Radiation and Immune Therapy
Brendan D. Curti, MD – Earle A. Chiles Research Institute, Providence Cancer Center
|
2:20 pm - 2:50 pm
|
Biomarkers: How to Select the Correct Patient for Which Therapy
Gregory A. Daniels, MD, PhD – University of California San Diego Cancer Center
|
2:50 pm - 3:20 pm
|
Panel Discussion and Case Studies
|
3:20 pm - 3:30 pm
|
Closing Remarks
|
Program Organizers
• Gregory A. Daniels, MD, PhD – University of California San Diego Cancer Center
• Omid Hamid, MD – The Angeles Clinic and Research Institute
Register By August 5, 2014 for Discounted Early Registration
Members are eligible for discounted registration rates. To receive the discounted rates listed below, your membership dues must be current through 2014. To renew your dues or apply for membership, please click here: www.sitcancer.org/membership
Member Early Rates
|
|
Student/Allied Health
|
FREE
|
Clinician/Academic
|
$50.00
|
Government
|
$50.00
|
Industry
|
$280.00
|
|
|
Non-Member Early Rates
|
|
Student/Allied Health
|
FREE
|
Clinician/Academic |
$50.00
|
Government |
$75.00
|
Industry |
$350.00
|
Remember! After the completion of the program, attendees will have free online access to program slides.
CME Credits Available
The Clinical Immunology Society designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™. For full accreditation information, visit: www.sitcancer.org/sitc-meetings/aci2014/ca/aci-ca-cme-information |
Society for Immunotherapy of Cancer (SITC)
555 East Wells Street, Suite 1100 | Milwaukee, Wisconsin 53202-3823 USA
Phone: +1 414 271 2456 | Email: info@sitcancer.org
© 2014 Society for Immunotherapy of Cancer
Join us on:
You have received this message because you have had previous contact with the Society for Immunotherapy of Cancer. If you do not wish to be included in our mailing list, please forward this message to info@sitcancer.org with the word "Remove" in the subject line.
Please add info@sitcancer.org to your safe senders list.
|